iBio
Kristi Sarno currently serves as Senior Vice President of Business Development at iBio, Inc., a role assumed in August 2024. Previously, Kristi owned KMSarno Consulting for a short period and held the position of Vice President of Business Development and Corporate Strategy at Homology Medicines, Inc. from January 2021 to August 2024, where contributions included the integration of AAV capabilities into a new manufacturing business. Earlier experience includes Senior Director roles in Business Development at Pfenex Inc. and Latham BioPharm Group, where Kristi focused on strategic analysis and market insights. Kristi holds a Master of Science in Virology from Harvard University and a Bachelor of Science in Biology from Syracuse University.
This person is not in any teams
This person is not in any offices
iBio
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming™ and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce COVID-19 biologics.